Clinical trials: Clear Cell Kidney Cancer
Clear Cell Metastatic Renal Cell Carcinoma
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
Disease and Stage: naïve metastatic kidney cancer. A multicenter, randomized, a Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer
- Trial name
- BIONIKK (NCT02960906)
- Testing
- Nivolumab, Ipilimumab, Pazopanib
- Where
- 16 sites in France
- Volunteers
- 200 people
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma
CAIX-targeted PET/CT in Solid Tumors
Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance.
- Conditions
- Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma, Lung Cancer (NSCLC), Breast Cancer
- Trial name
- CAIX-PET (NCT07833085)
- Testing
- 68Ga-CAIX
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Ivonescimab, Clear Cell Renal Carcinoma
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ccRCC.
- Trial name
- NCT06940518
- Testing
- Ivonescimab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Clear Cell Renal Cell Carcinoma
68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
Radiation therapy (RT) is an effective treatment for patients with advanced-stage clear cell renal cell carcinoma (ccRCC). Current evidence has shown promising outcomes combining radiation therapy and standard systemic therapy in…
- Trial name
- NYCRRT (NCT06613269)
- Testing
- 68Ga-NY104 PET/CT, 18F-FDG PET/CT, Radiation Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Clear Cell Renal Cell Carcinoma
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
There are 2 parts to this clinical research study: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The goal of Part 1 is to find the recommended dose of LNK001 in patients with advanced or metastatic ccRCC.
- Trial name
- NCT07564232
- Testing
- Cyclophosphamide, Fludarabine, LNK001
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Clear Cell Sarcoma of the Kidney, Recurrent Renal Cell Carcinoma
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of dalteparin when given together with sunitinib malate in treating patients with kidney cancer that has spread to other parts of the body or cannot be removed by surgery.
- Conditions
- Clear Cell Sarcoma of the Kidney, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01061411
- Testing
- Dalteparin, Pharmacological Study, Sunitinib Malate
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Carbonic Anhydrase IX, PET-CT
68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 68Ga-C1 in PET/CT imaging in clear cell renal cell carcinoma patients.
- Conditions
- Carbonic Anhydrase IX, PET-CT, Clear Cell Renal Cell Carcinoma
- Trial name
- NCT06519760
- Testing
- 68Ga-C1
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Clear-cell Metastatic Renal Cell Carcinoma
Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer
This study is designed as a phase-II proof of clinical trial to investigate if a treatment strategy where stereotactic body radiation therapy (SBRT) is given with pembrolizumab is sufficiently active to warrant further…
- Trial name
- NCT05567588
- Testing
- Drug: Pembrolizumab
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
This phase I/II trial tests the safety and effectiveness of inulin gel in combination with ipilimumab and nivolumab in treating patients with kidney cell cancer (renal cell carcinoma [RCC]) that has spread from where it first…
- Conditions
- Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma
- Trial name
- NCT06866262
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Michigan Rogel Cancer Center
Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's…
- Conditions
- Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model, Recurrent Renal Cell Cancer
- Trial name
- NCT06088134
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Mingzhao Xiao
Renal Cell Carcinoma
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by…
- Trial name
- CLEAR (NCT02811861)
- Testing
- Lenvatinib, Everolimus, Pembrolizumab
- Where
- 183 sites in United States, Australia and 18 more
- Volunteers
- 1,069 people
- Sponsor
- Eisai Inc.
Renal Cell Carcinoma
Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
This is a pilot, single-center, single-arm study where 20 patients with metastatic or unresectable clear cell renal cell carcinoma will receive same sequential treatment strategy (Cabozantinib for 12 weeks, then proceed with…
- Trial name
- NCT05188118
- Testing
- Cabozantinib, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Clear Cell Renal Cell Carcinoma
89Zr-DFO-girentuximab Expanded Access Program (EAP)
The purpose of this Expanded Access Program (EAP) is to enable the use of 89Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9…
- Trial name
- NCT06090331
- Testing
- 89Zr-DFO-girentuximab
- Where
- 22 sites in United States
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Clear Cell Renal Cell Carcinoma
Combination of Toripalimab and JS004 Therapy for ccRCC
This study is a single center, prospective, randomized controlled phase II clinical trial aimed at examining the efficacy and safety of the combination of toripalimab and JS004 versus standard therapy for second-line treatment of…
- Trial name
- NCT06690697
- Testing
- JS004, Toripalimab, Axitinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Clear Cell Renal Cell Carcinoma
Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma
This is a phase II, open-label, multicenter, single-arm study evaluating the efficacy and safety of cadonilimab (AK104) in combination with lenvatinib in patients with unresectable advanced or metastatic clear cell renal cell…
- Trial name
- NCT06035224
- Testing
- AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
- Where
- China
- Volunteers
- 28 people
- Sponsor
- RenJi Hospital
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer
This phase II trial is studying how well AZD2171 works in treating patients with refractory metastatic kidney cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by…
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00303862
- Testing
- cediranib maleate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic renal cell carcinoma is discussed.
- Trial name
- NCT01182142
- Testing
- Capecitabine
- Where
- Russia
- Volunteers
- 51 people
- Sponsor
- Kidney Cancer Research Bureau
Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer…
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- PROBE (NCT04510597)
- Testing
- Cytoreductive Nephrectomy, Active Comparator
- Where
- 387 sites in United States
- Volunteers
- 364 people
- Sponsor
- SWOG Cancer Research Network
Advanced Clear Cell Renal Carcinoma
Vandetanib to Treat Advanced Kidney Cancer
Background: One way tumors are able to grow is by forming new blood vessels that supply it with nutrients and oxygen. Vandetanib (ZD6474) is an experimental drug that blocks certain proteins on the surface of tumor and blood…
- Trial name
- NCT01372813
- Testing
- vandetanib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)